Four selected trials examine mazdutide in adults with obesity or type 2 diabetes in China and the United States. Trial populations, comparators and statistical estimands differ and should not be used to rank results across studies.1234
Bottom line from this bounded source set
Randomized trials reported weight and glucose-control improvements in the studied populations, with gastrointestinal adverse events. These publications do not by themselves establish regulatory status, long-term complications or comparative effectiveness outside their specific designs.1234
610 adults with overweight or obesity participated.1
Outcomes reported
At week 32, intention-to-treat weight changes were −10.09% and −12.55% in active groups versus +0.45% with placebo. Gastrointestinal adverse events were common; adverse-event discontinuation occurred in 1.5%, 0.5% and 1.0%, respectively.1
Limitations
The study concerns its enrolled population and prespecified follow-up. Weight change alone cannot establish cardiovascular benefit or longer-term safety.1
Reviewed study record
Type 2 diabetes: active comparator
Design
Randomized phase 3 comparison with a specified dulaglutide regimen over 28 weeks.2
Population
731 adults in China with type 2 diabetes participated.2
Outcomes reported
Between-group HbA1c differences favored the two mazdutide groups by 0.24 and 0.30 percentage points; reductions in percentage body-weight change were 3.78 and 5.76 percentage points greater than with dulaglutide. Gastrointestinal events were more frequent with mazdutide.2
Limitations
The comparison is specific to the tested regimens and population, not a ranking against all uses of the comparator or other medicines.2
Reviewed study record
Type 2 diabetes: placebo comparison
Design
Randomized, double-blind phase 3 trial with a 24-week primary comparison.3
Population
320 adults in China with type 2 diabetes participated.3
Outcomes reported
HbA1c changes were −1.57 and −2.15 percentage points versus −0.14 with placebo. Gastrointestinal events were common.3
Limitations
The subsequent extension is follow-up of this study, not a separate randomized experiment. Biomarker changes do not establish reduced complications.3
Reviewed study record
US phase 2 obesity trial
Design
Randomized, placebo-controlled phase 2 trial with a week-32 primary endpoint and longer follow-up.4
Population
179 adults with overweight or obesity participated.4
Outcomes reported
The reported hypothetical-estimand weight changes at week 32 were −7.3%, −15.6% and −18.1% versus −0.9%. Adverse events led to discontinuation in 20% of the highest active group.4
Limitations
A hypothetical estimand is not the same as observed outcomes regardless of discontinuation. Population, follow-up and estimand differences prevent direct comparison with GLORY-1.4
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1056/nejmoa2411528. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1038/s41586-025-10031-z. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1038/s41586-025-10026-w. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s2213-8587(26)00160-9. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗